Business Context and Reporting Period
The filing is Nanophase Technologies Corporation’s unaudited Form 10-Q for the quarter ended September 30, 2012, with comparisons to the three- and nine-month periods ended September 30, 2011. The filing describes a nanomaterials developer and manufacturer serving personal care, coatings, polishing, and other markets. The request metadata names SOLESENCE, INC.; this does not match the registrant identified in the filing and should be verified.
Financial Performance and Liquidity
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Net revenue | $2.10 million | $2.24 million | $7.29 million | $7.95 million |
| Gross profit | $529,389 | $348,913 | $1.94 million | $2.25 million |
| Gross margin | 25.2% | 15.6% | 26.6% | 28.3% |
| Operating loss | $656,283 | $1.01 million | $1.81 million | $2.09 million |
| Net loss | $658,339 | $1.01 million | $1.81 million | $2.09 million |
- Revenue fell 6.3% in Q3 and 8.3% for the nine-month period year over year. Q3 gross margin improved, while nine-month gross margin declined.
- For the first nine months, operating cash use was $201,791, versus $2.32 million in 2011. Investing cash use was $131,910; financing provided $2.21 million, principally from the rights offering. Cash rose to $4.57 million from $2.69 million at year-end 2011.
- At September 30, cash, cash equivalents, and restricted short-term investments totaled $4.60 million. Current assets were $7.03 million and current liabilities $1.30 million. Capital lease obligations totaled approximately $106,000; the company reported no debt.
- On July 20, 2012, the company completed a fully subscribed rights offering of 7.25 million shares at $0.33 per share, receiving approximately $2.2 million net. Shares outstanding increased to 28.46 million from 21.21 million at year-end 2011.
Material Changes, Outlook, and Risks
- Management attributed lower revenue primarily to the timing of sales to major customers. Cost of revenue and operating expenses also declined; lower SG&A reflected reduced personnel-related, consulting, legal, stock-compensation, and trade-show costs.
- Revenue is highly concentrated: the largest customer contributed 62% of Q3 revenue and 68% for the nine months. BASF is the largest customer and has contractual rights that could allow technology transfer and equipment purchase if specified conditions are triggered. One trigger involves negative trailing-12-month earnings together with cash, cash equivalents, and certain investments below $2 million; the company reported approximately $4.6 million in these resources and no debt at quarter-end.
- Management said available cash and operating cash flows should fund plans through 2012 and into 2013. It expected approximately $100,000 of capital spending for the remainder of 2012 if certain projects proceed. Future funding needs depend on customer demand, development progress, and manufacturing requirements; additional financing may be unavailable or dilutive.
- Management expected growth in customer adoption and new markets, but noted that revenue timing and commercial success are uncertain. Margins depend on sales volume and mix, cost reductions, and the ability to pass through raw-material increases. Cerium oxide costs had fallen from 2011 peaks but remained several times higher than two years earlier; supply and cost remain risks.
- The Japanese licensee prepaid $279,000 toward a final minimum royalty; $67,998 remained deferred at September 30. Existing agreements were expected to terminate March 31, 2013, after which territorial restrictions and royalty payments would end.
- The company reported ongoing net losses and approximately $79.9 million of tax net operating loss carryforwards, some of which may expire unused or be limited. No legal proceedings were reported. Management concluded disclosure controls were effective; no material change in internal control over financial reporting was reported.
Important Facts to Verify
- Confirm that the filing is for Nanophase Technologies Corporation, not SOLESENCE, INC., as stated in the request metadata.
- Assess the sustainability of the Q3 gross-margin improvement against the weaker nine-month margin and continued operating losses.
- Review BASF’s financial and performance triggers, customer concentration, and the potential operational impact of a technology transfer or equipment sale.
- Verify cash runway, working-capital needs, and the timing and economics of expected customer and new-market growth.
- Evaluate exposure to cerium oxide supply and pricing, and the revenue implications of the Japanese license agreements ending in 2013.